Cited 0 times in
Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박경수 | - |
dc.contributor.author | 박민수 | - |
dc.contributor.author | 이상학 | - |
dc.contributor.author | 정재용 | - |
dc.date.accessioned | 2014-12-19T16:56:00Z | - |
dc.date.available | 2014-12-19T16:56:00Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90464 | - |
dc.description.abstract | OBJECTIVE: The aim of this study was to develop a longitudinal pharmacodynamic model describing the time-courses of low-density lipoprotein cholesterol (LDL) profiles during and after atorvastatin treatment in Korean dyslipidemic patients and non-patient volunteers. METHODS: 15 dyslipidemic patients and 11 non-patient volunteers with no prior therapy participated in a parallel, 2-step dose escalation study. Subjects received atorvastatin doses ranging from 10 to 80 mg for 42 days (dyslipidemic patients) or 10 mg for 21 days (non-patient volunteers). Plasma samples were collected before and during the treatment period and up to 2 weeks after the last administration. A population pharmacodynamic model was built using the NONMEM software package. An indirect response model consisting of production in hepatocyte and elimination from plasma stimulated by atorvastatin described the LDL time-course. RESULTS: The typical population value of the estimated dose producing 50% of maximal stimulation on LDL elimination (SD50) for dyslipidemic patients was 11.9 mg, which was about 6 times higher than that of non-patient volunteers (2.0 mg). CONCLUSION: A longitudinal population pharmacodynamic model for the LDL-lowering effect of atorvastatin in both dyslipidemic patients and non-patient volunteers was developed. This could help guide optimal therapies according to the target population. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Asian Continental Ancestry Group* | - |
dc.subject.MESH | Atorvastatin Calcium | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Cholesterol, LDL/blood* | - |
dc.subject.MESH | Computer Simulation | - |
dc.subject.MESH | Decision Support Techniques | - |
dc.subject.MESH | Down-Regulation | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Drug Dosage Calculations | - |
dc.subject.MESH | Dyslipidemias/blood | - |
dc.subject.MESH | Dyslipidemias/drug therapy* | - |
dc.subject.MESH | Dyslipidemias/ethnology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Heptanoic Acids/administration & dosage | - |
dc.subject.MESH | Heptanoic Acids/blood | - |
dc.subject.MESH | Heptanoic Acids/pharmacokinetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Models, Biological* | - |
dc.subject.MESH | Pyrroles/administration & dosage | - |
dc.subject.MESH | Pyrroles/blood | - |
dc.subject.MESH | Pyrroles/pharmacokinetics* | - |
dc.subject.MESH | Republic of Korea/epidemiology | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학) | - |
dc.contributor.googleauthor | Eun Sil Oh | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.contributor.googleauthor | Min Soo Park | - |
dc.contributor.googleauthor | Kyungsoo Park | - |
dc.contributor.googleauthor | Jae-Yong Chung | - |
dc.identifier.doi | 22981146 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01422 | - |
dc.contributor.localId | A01468 | - |
dc.contributor.localId | A03709 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J01098 | - |
dc.identifier.pmid | 22981146 | - |
dc.identifier.url | http://www.dustri.com/index.php?id=98&artId=9968 | - |
dc.subject.keyword | modeling | - |
dc.subject.keyword | LDL-lowering | - |
dc.subject.keyword | pharmacodynamics | - |
dc.subject.keyword | atorvastatin | - |
dc.subject.keyword | NONMEM | - |
dc.contributor.alternativeName | Park, Kyung Soo | - |
dc.contributor.alternativeName | Park, Min Soo | - |
dc.contributor.alternativeName | Lee, Sang Hak | - |
dc.contributor.alternativeName | Chung, Jae Yong | - |
dc.contributor.affiliatedAuthor | Park, Kyung Soo | - |
dc.contributor.affiliatedAuthor | Park, Min Soo | - |
dc.contributor.affiliatedAuthor | Chung, Jae Yong | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.citation.volume | 50 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 647 | - |
dc.citation.endPage | 656 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, Vol.50(9) : 647-656, 2012 | - |
dc.identifier.rimsid | 32780 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.